Skip Nav Destination
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation
Issue Archive
December 18 2014
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Clinical Trials & Observations
Peter Dreger,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Johannes Schetelig,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Niels Andersen,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Paolo Corradini,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Michel van Gelder,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),John Gribben,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Eva Kimby,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Mauricette Michallet,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Carol Moreno,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Stephan Stilgenbauer,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT),Emili Montserrat,on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
EVIDENCE-BASED FOCUSED REVIEW
HOW I TREAT
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial
Clinical Trials & Observations
Dieter Hoelzer,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Jan Walewski,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Hartmut Döhner,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Andreas Viardot,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Wolfgang Hiddemann,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Karsten Spiekermann,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Hubert Serve,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Ulrich Dührsen,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Andreas Hüttmann,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Eckhard Thiel,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Jolanta Dengler,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Michael Kneba,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Markus Schaich,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Ingo G. H. Schmidt-Wolf,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Joachim Beck,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Bernd Hertenstein,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Albrecht Reichle,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Katarzyna Domanska-Czyz,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Rainer Fietkau,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Heinz-August Horst,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Harald Rieder,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Stefan Schwartz,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Thomas Burmeister,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia,Nicola Gökbuget,for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Clinical Trials & Observations
Peter W. Collins,for the paradigm 2 Investigators,Guy Young,for the paradigm 2 Investigators,Karin Knobe,for the paradigm 2 Investigators,Faraizah Abdul Karim,for the paradigm 2 Investigators,Pantep Angchaisuksiri,for the paradigm 2 Investigators,Claus Banner,for the paradigm 2 Investigators,Türkiz Gürsel,for the paradigm 2 Investigators,Johnny Mahlangu,for the paradigm 2 Investigators,Tadashi Matsushita,for the paradigm 2 Investigators,Eveline P. Mauser-Bunschoten,for the paradigm 2 Investigators,Johannes Oldenburg,for the paradigm 2 Investigators,Christopher E. Walsh,for the paradigm 2 Investigators,Claude Negrier,for the paradigm 2 Investigators
HEMATOPOIESIS AND STEM CELLS
Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice
Elise Peterson Lu,Michael McLellan,Li Ding,Robert Fulton,Elaine R. Mardis,Richard K. Wilson,Christopher A. Miller,Peter Westervelt,John F. DiPersio,Daniel C. Link,Matthew J. Walter,Timothy J. Ley,Timothy A. Graubert
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Both mature KIR+ and immature KIR− NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice
Ayline Kübler,Jeanette Woiterski,Kai-Erik Witte,Hans-Jörg Bühring,Udo F. Hartwig,Martin Ebinger,Lena Oevermann,Markus Mezger,Wolfgang Herr,Peter Lang,Rupert Handgretinger,Christian Münz,Maya C. André
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons
Jiajia Pan,Larissa Lordier,Deborah Meyran,Philippe Rameau,Yann Lecluse,Susan Kitchen-Goosen,Idinath Badirou,Hayat Mokrani,Shuh Narumiya,Arthur S. Alberts,William Vainchenker,Yunhua Chang
RED CELLS, IRON, AND ERYTHROPOIESIS
Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation
Brief Report
Hao Xu,Nancy J. Wandersee,YiHe Guo,Deron W. Jones,Sandra L. Holzhauer,Madelyn S. Hanson,Evans Machogu,David C. Brousseau,Neil Hogg,John C. Densmore,Sushma Kaul,Cheryl A. Hillery,Kirkwood A. Pritchard, Jr
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation
Effie W. Petersdorf,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Theodore A. Gooley,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Mari Malkki,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Andrea P. Bacigalupo,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Anne Cesbron,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Ernette Du Toit,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Gerhard Ehninger,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Torstein Egeland,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Gottfried F. Fischer,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Thibaut Gervais,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Michael D. Haagenson,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Mary M. Horowitz,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Katharine Hsu,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Pavel Jindra,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Alejandro Madrigal,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Machteld Oudshoorn,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Olle Ringdén,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Marlis L. Schroeder,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Stephen R. Spellman,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Jean-Marie Tiercy,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Andrea Velardi,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Campbell S. Witt,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Colm O’Huigin,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Richard Apps,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation,Mary Carrington,for the International Histocompatibility Working Group in Hematopoietic Cell Transplantation
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Tubulin polymerization assays showed that myosin II inhibition by blebbistatin (25 μM) disturbed stress fiber formation but increased tubulin polymerization in CD41+ megakaryocytes (MKs). MKs were stained for tubulin (α and β [green]) and phalloidin-TRITC (red); DNA was stained with TOTO (blue). See the article by Pan et al on page 3967.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals